Refine
Year of publication
Document Type
- Preprint (599)
- Article (360)
- Review (6)
- Conference Proceeding (2)
- Part of a Book (1)
- Working Paper (1)
Has Fulltext
- yes (969)
Keywords
- Heavy Ion Experiments (18)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Hadron-Hadron Scattering (7)
- Heavy-ion collision (6)
- Rezension (6)
- ALICE experiment (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Heavy Ions (3)
Institute
- Physik (946)
- Frankfurt Institute for Advanced Studies (FIAS) (873)
- Informatik (839)
- Medizin (11)
- Informatik und Mathematik (3)
- Extern (2)
- Hochschulrechenzentrum (2)
- Biochemie und Chemie (1)
- Biowissenschaften (1)
- Center for Financial Studies (CFS) (1)
This report provides a brief review of the 20th annual meeting of the German Language Branch of the Society of Environmental Toxicology and Chemistry (SETAC GLB) held from September 7th to 10th 2015 at ETH (Swiss Technical University) in Zurich, Switzerland. The event was chaired by Inge Werner, Director of the Swiss Centre for Applied Ecotoxicology (Ecotox Centre) Eawag-EPFL, and organized by a team from Ecotox Centre, Eawag, Federal Office of the Environment, Federal Office of Agriculture, and Mesocosm GmbH (Germany). Over 200 delegates from academia, public agencies and private industry of Germany, Switzerland and Austria attended and discussed the current state of science and its application presented in 75 talks and 83 posters. In addition, three invited keynote speakers provided new insights into scientific knowledge ‘brokering’, and—as it was the International Year of Soil—the important role of healthy soil ecosystems. Awards were presented to young scientists for best oral and poster presentations, and for best 2014 master and doctoral theses. Program and abstracts of the meeting (mostly in German) are provided as Additional file 1.
Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting.
Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm).
Conclusions: Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.
Background: Unlike metastatic colorectal cancer (CRC) there are to date few reports concerning the predictive value of molecular biomarkers on the clinical outcome in stage II/III CRC patients receiving adjuvant chemotherapy. Aim of this study was to assess the predictive value of proteins related with the EGFR- and VEGFR- signalling cascades in these patients.
Methods: The patients' data examined in this study were from the collective of the 5-FU/FA versus 5-FU/FA/irinotecan phase III FOGT-4 trial. Tumor tissues were stained by immunohistochemistry for VEGF-C, VEGF-D, VEGFR-3, Hif-1 α, PTEN, AREG and EREG expression and evaluated by two independent, blinded investigators. Survival analyses were calculated for all patients receiving adjuvant chemotherapy in relation to expression of all makers above.
Results: Patients with negative AREG and EREG expression on their tumor had a significant longer DFS in comparison to AREG/EREG positive ones (p< 0.05). The benefit on DFS in AREG-/EREG- patients was even stronger in the group that received 5-FU/FA/irinotecan as adjuvant treatment (p=0.002). Patients with strong expression of PTEN profited more in terms of OS under adjuvant treatment containing irinotecan (p< 0.05). Regarding markers of the VEGFR- pathway we found no correlation of VEGF-C- and VEGFR-3 expression with clinical outcome. Patients with negative VEGF-D expression had a trend to live longer when treated with 5-FU/FA (p=0.106). Patients who were negative for Hif-1 α, were disease-free in more than 50% at the end of the study and showed significant longer DFS-rates than those positive for Hif-1 α (p=0.007). This benefit was even stronger at the group treated with 5-FU/FA/irinotecan (p=0.026). Finally, AREG-/EREG-/PTEN+ patients showed a trend to live longer under combined treatment combination.
Conclusions: The addition of irinotecan to adjuvant treatment with 5-FU/FA does not provide OS or DFS benefit in patients with stage II/III CRC. Nevertheless, AREG/EREG negative, PTEN positive and Hif-1 α negative patients might profit significantly in terms of DFS from a treatment containing fluoropyrimidines and irinotecan. Our results suggest a predictive value of these biomarkers concerning adjuvant chemotherapy with 5-FU/FA +/− irinotecan in stage II/III colorectal cancer.
Aus postkolonialer Perspektive gilt der Exotismus im Anschluss an Edward Said als die spezifische Ästhetik des Imperialismus, als Projektion westlicher Wunschphantasien, als ästhetische Ausbeutung des Fremden im Imperium der westlichen Kulturproduktion. Von einem „Ausstieg aus dem kolonialen Syndrom“, mithin von Postkolonialismus, könne man erst sprechen, wenn die diskursive Strategie des Exotismus nicht mehr funktioniere. Die einschlägigen literaturwissenschaftlichen Nachschlagewerke erklären, dass der Begriff Exotismus als Entlehnung aus dem Französischen zu Beginn des 20. ahrhunderts Eingang in die deutsche Sprache gefunden habe. Gerhart Pickerodt verweist im Reallexikon der deutschen Literaturwissenschaft auf „früheste bekannte Belege“ bei dem österreichischen Expressionisten Robert Müller aus dem Jahr 1914.
Rezension zu Eva Blome: Reinheit und Vermischung. Literarisch-kulturelle Entwürfe von "Rasse" und Sexualität (1900-1930). Köln (Böhlau) 2011. 354 S.
Zentral für die am Konstanzer Graduiertenkolleg 'Die Figur des Dritten' entstandene Dissertation ist die um 1900 von der Eugenik aufgeworfene Frage, ob der 'Neue Mensch' eher 'gemischtrassig' oder 'rassenrein' sein soll.
Rezension zu Sabina Becker: Literatur- und Kulturwissenschaften. Ihre Methoden und Theorien. Reinbek b. Hamburg (Rowohlt) 2007 (=Rowohlt Enzyklopädie, Bd. 55686). 223 S.
Sabina Becker, Professorin für germanistische Literaturwissenschaft an der Universität Freiburg, hat mit diesem Buch eine kleine, aber feine Methoden-Enzyklopädie vorgelegt. Zwar kommt es zu Wiederholungen, wenn einzelne Methoden gegeneinander abgegrenzt werden, aber daraus ergibt sich der Vorteil, dass jeder Eintrag auch für sich gelesen werden kann. Die 19 Abschnitte des Buches reichen von Gadamers Hermeneutik bis Bourdieus Kultursoziologie, erschlossen werden kann es auch über ein Personen- und Sachregister.
Die Habilitation des Berner Literaturwissenschaftlers Matthias N. Lorenz untersucht die intertextuelle Auseinandersetzung mit Joseph Conrads "Heart of Darkness" (1899) im deutschen Sprachraum. Intertextualität fasst Lorenz im Anschluss an Ulrich Broich und Manfred Pfister als "bewusst intendierte" und "deutlich signalisierte Beziehungen" zwischen Texten. In einem 'close reading' kommen zunächst Zeitgenossen Conrads zur Sprache. Auf eine Latenzzeit der Conrad-Rezeption in der Nachkriegszeit folgt in den 80er Jahren eine Renaissance. Das längste Kapitel ist den Conrad-Lektüren von sieben Autorinnen und Autoren aus den Jahren 1986-2012 gewidmet. Hier leuchtet Lorenz feministische, kapitalismuskritische und postkoloniale Transformationen von "Heart of Darkness" aus. Schließlich rückt das Thema der Traumatisierung von Europäern in der Konfrontation mit Gewalt in Afrika in den Mittelpunkt der Betrachtung.
[D]ieser Veranstaltungstyp [wurde] 1996 etabliert […] und die komparatistisch angelegte Konferenz der Abteilung 2012 [wird] nunmehr zum 17. Mal in Folge ausgerichtet […]. Über den Kreis der 15 Referenten hinaus war sie mit etwa 120 aktiv mitdiskutierenden Teilnehmern gut besucht. Thematisch orientiert sich die Konferenz jeweils an einem Semesterkurs, den die Studierenden der am Department angebotenen Master‐Studiengänge (Deutsch, Französisch, Spanisch, Italienisch) durchlaufen.
Rezension zu Volker Zenk: Innere Forschungsreisen. Literarischer Exotismus in Deutschland zu Beginn des 20. Jahrhunderts, Oldenburg (Igel Verlag Wissenschaft) 2003 (= Literatur- und Medienwissenschaft; Bd. 89). 424 Seiten.
Mit seiner Dissertation legt der Autor eine Synthese der in den letzten Jahren zunehmend in Einzeluntersuchungen zerstreuten Forschung zur exotistischen Literatur der Jahrhundertwende vor.